Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Finch Therapeutics Group stock in Canada | $13.75

Own Finch Therapeutics Group shares in just a few minutes.

Finch Therapeutics Group is a biotechnology business based in the US. Finch Therapeutics Group stocks (FNCH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.77 – an increase of 2.61% over the previous week. Finch Therapeutics Group employs 186 staff and has a trailing 12-month revenue of around $10 million.

How to buy Finch Therapeutics Group stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: FNCH in this case.
  5. Research Finch Therapeutics Group stocks. The platform should provide the latest information available.
  6. Buy your Finch Therapeutics Group stocks. It's that simple.

Is it a good time to buy Finch Therapeutics Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Finch Therapeutics Group stock price

Use our graph to track the performance of FNCH stocks over time.

Finch Therapeutics Group stocks at a glance

Information last updated 2021-09-10.
Latest market close$13.75
52-week range$11.56 - $22.5
50-day moving average $13.9171
200-day moving average $14.5718
Wall St. target price$29.67
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.675

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Finch Therapeutics Group price performance over time

Historical closes compared with the last close of $13.75

1 week (2021-09-10) 2.61%
1 month (2021-08-17) 7.59%
3 months (2021-06-18) -14.06%
6 months (2021-03-18) -19.12%

Finch Therapeutics Group financials

Revenue TTM USD$10 million
Gross profit TTM USD$-25,425,000
Return on assets TTM -18.33%
Return on equity TTM -35.61%
Profit margin 0%
Book value $4.812
Market capitalisation USD$635.8 million

TTM: trailing 12 months

How to short and sell Finch Therapeutics Group stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "FNCH.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 292,782 Finch Therapeutics Group stocks held short by investors – that's known as Finch Therapeutics Group's "short interest". This figure is 31.1% down from 424,634 last month.

There are a few different ways that this level of interest in shorting Finch Therapeutics Group stocks can be evaluated.

Finch Therapeutics Group's "short interest ratio" (SIR)

Finch Therapeutics Group's "short interest ratio" (SIR) is the quantity of Finch Therapeutics Group stocks currently shorted divided by the average quantity of Finch Therapeutics Group stocks traded daily (recently around 50133.904109589). Finch Therapeutics Group's SIR currently stands at 5.84. In other words for every 100,000 Finch Therapeutics Group stocks traded daily on the market, roughly 5840 stocks are currently held short.

However Finch Therapeutics Group's short interest can also be evaluated against the total number of Finch Therapeutics Group stocks, or, against the total number of tradable Finch Therapeutics Group stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Finch Therapeutics Group's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Finch Therapeutics Group stocks in existence, roughly 10 stocks are currently held short) or 0.0159% of the tradable stocks (for every 100,000 tradable Finch Therapeutics Group stocks, roughly 16 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Finch Therapeutics Group.

Find out more about how you can short Finch Therapeutics Group stock.

Finch Therapeutics Group stock dividends

We're not expecting Finch Therapeutics Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Finch Therapeutics Group overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Stocks similar to Finch Therapeutics Group

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site